New York Times has reported that Pharmaceutical firm, Pfizer, has revealed that an initial evaluation of the trial of the COVID-19 vaccine it was producing showed that the vaccine was effective in fighting the disease. This is a major breakthrough for the world as it had for a long time anticipated a favourable development in respect of the pandemic has killed more than 1.2 million people.
Pfizer in conjunction with German drugmaker, BioNTech, issued a few information from the trial based on the initial official evaluation of the data carried out by a team of neutral pundits.
According to the information released, the review found out that the vaccine’s effectiveness in preventing the disease among volunteers without prior record of coronavirus infection is above 90 percent.
Kathrin Jansen, a Senior Vice President and Head of Vaccine Research and Development said: “This is a historical moment.
“This was a devastating situation, a pandemic, and we have embarked on a path and a goal that nobody ever has achieved — to come up with a vaccine within a year.”
All things being equal, the extent of this protection will put it at par with childhood vaccines of high efficacy for diseases such as measles. Pfizer also said that no serious safety fears had been noted so far.
Pfizer looks to obtain emergency approval for the two-dose vaccine from the Food and Drug Administration in the coming days after it has collected the prescribed two months of safety data.
The Executives of the company said enough doses to immunise between 15 and 20 million people would have been manufactured by the end of this year.
